CASI Pharmaceuticals Stock Statistic Functions Linear Regression Angle
| CASI Stock | USD 0.24 -0.06 -20.00% |
| Symbol |
We are not able to run technical analysis function on this symbol. We either do not have that equity or its historical data is not available at this time. Please try again later.
CASI Pharmaceuticals Technical Analysis Modules
Most technical analysis of CASI Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for CASI from various momentum indicators to cycle indicators. When you analyze CASI charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people. Liquidity and trading activity can influence how quickly new information is reflected in CASI Pharmaceuticals's price. Lower liquidity may increase execution variability. CASI Pharmaceuticals has market cap of 3.21 M, ROE of -10.94%.
Methodology
Unless otherwise specified, financial data for CASI Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. CASI (USA Stocks:CASI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
CASI Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Learn to be your own money manager
Tracking CASI Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
CASI Pharmaceuticals pair trading
Pair trading with CASI Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
CASI Pharmaceuticals Pair Trading
CASI Pharmaceuticals Pair Trading Analysis
Pair-trading logic also applies to tax-loss harvesting: by identifying an asset with near-identical factor exposures to CASI Pharmaceuticals, investors can effectively maintain a synthetic CASI Pharmaceuticals position while the wash-sale clock resets.
The correlation structure around CASI Pharmaceuticals evolves as market regimes change. Assets that were once uncorrelated with CASI Pharmaceuticals may become correlated during crises, so investors should monitor rolling correlations alongside static long-run averages.
Pair evaluation and Correlation analysis for CASI Pharmaceuticals provide hedging context. The approach can be applied within sectors or across broader universes.More Resources for CASI Stock Analysis
Reviewing CASI Pharmaceuticals commonly begins with financial statements and performance trends. Ratios and trend metrics help frame CASI Pharmaceuticals' operating context. Outlined below are key reports that provide context for CASI Pharmaceuticals Stock:CASI Pharmaceuticals has market cap of 3.21 M, operating margin of -3.33%, ROE of -10.94%. Trending Equities can help frame allocation decisions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Analysis related to CASI Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Earnings Share -3.02 | Revenue Per Share | Quarterly Revenue Growth -0.60 | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value and book value, each describing different facets of the business. CASI Pharmaceuticals' market capitalization is 3.21 M. With a P/B ratio of 11.21, the market values CASI Pharmaceuticals well above its book equity. Enterprise value stands at 18.49 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for CASI Pharmaceuticals are related but not identical, and they can diverge across cycles. For CASI Pharmaceuticals, key inputs include a P/B ratio of 11.21, a profit margin of -1.84%, ROE of -10.94%, and revenue of 28.54 M. Market price reflects the current exchange level formed by active bids and offers.